As technological advances have made seismic changes to the pharmaceutical sector, no element of the industry has been left untouched, and labelling is no exception. What was once a straightforward process of printing product information has evolved into a complex, discipline that sits at the intersection of patient safety, regulatory compliance and supply chain security. And this is only becoming more intricate as counterfeit medicines become increasingly widespread and regulations become more strict across multiple jurisdictions.
For global pharmaceutical organisations, the stakes have never been higher. Failing to comply with labelling regulations can result in product recalls, market access delays, substantial financial penalties and irreparable damage to brand reputation. Yet achieving compliance across the multiple international markets European Union, China, India, and other major markets requires navigating a labyrinth of serialisation mandates, track-and-trace requirements and everchanging regulatory frameworks.


